# OnCo record vepdegestrant (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vepdegestrant/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vepdegestrant" ;
  schema:name "Vepdegestrant"@en ;
  schema:description "Vepdegestrant is the first PROTAC ever approved (2026): a pill that tags the oestrogen receptor for destruction, for breast cancers with ESR1 mutations."@en ;
  schema:url <https://onco.cc/drugs/vepdegestrant/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vepdegestrant> ;
  onco:status "approved" ;
  onco:modality "PROTAC oestrogen receptor degrader" ;
  schema:alternateName "Veppanu" ;
  onco:approval "US 2026: ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/arvinas/>, <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/veritac-2/>, <https://onco.cc/trials/nct04606446/>, <https://onco.cc/trials/nct06206837/>, <https://onco.cc/trials/nct05548127/>, <https://onco.cc/trials/nct05909397/>, <https://onco.cc/trials/nct05573555/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-protac-concept-sakamoto-pnas-2001/> .